Commercial-scale gene therapy manufacturing
Viralgen Commercial is the next phase of an ambitious project established in 2017. Once completed, it will be the world’s largest manufacturing facility for adeno-associated vectors known as AAVs for use in the treatment of disease. Large-scale manufacturing will enable Viralgen to supply the product beyond clinical trials. In this way, Viralgen Commercial democratises access to gene therapy, both in volume and speed of production, by increasing yield and throughput while reducing manufacturing costs.
CEO: Javier García Cogorro.
2019-2021 (Sold to Bayer)